- Главная
- Аналитика приложений
- STEMIcathAID
- STEMIcathAID Vs. MCSAID
STEMIcathAID против MCSAID Использование & Stats
STEMIcathAID is a patient recognition, response, and record-keeping system designed to improve outcomes through adherence the American Heart Association’s Mission:Lifeline STEMI guidelines. Early restoration of blood flow to occluded coronary vessels has been shown to significantly improve outcomes for high-risk STEMI patients. STEMIcathAID aims to improve these clinical outcomes by optimizing their treatment following many of the recommendations of the AHA by reducing the time to STEMI recognition, lead acquisition, STEMI identification, notification of the catheterization lab, and reperfusion.
There are multiple personnel and steps involved in caring for these high-risk patients. STEMIcathAID takes an algorithmic approach which will enhance the coordination and communication tasks essential to rapid assessment and easy transfer of STEMI patients from the field or outside facility. It will also provide protocols for the EMS or outside hospital provider to identify patients in cardiogenic shock even before their arrival in the catheterization lab. The application will integrate live GPS tracking of the patients alongside the time the alarm was raised prompting the sense of urgency in transferring the patient.
Incorporating images, videos, illustrations, and live GPS tracking of the EMS, the design will be subdivided into three main sections:
1. EKG Upload by outside facility or EMS
2. Assessment of Cardiogenic Shock
3. STEMI patient transfer pathway
When a medical provider, in the field, other hospital, or outpatient office, suspects STEMI, the provider uploads the EKG by taking a picture of it with their phone. Once the EKG is uploaded, the on-call attending at the PCI-capable facility receives a notification from the application. If the attending believes the patient is experiencing a real STEMI, the pathway is activated. Upon activation, the approximately 10-12 people involved in taking care of the patient are notified so they can begin preparations. Adhering to HIPAA compliance, all users log into the encrypted application and begin to collaborate such aspects as patient vitals, shock information, and emergency vehicle current location and estimated arrival time to the cath lab.
Through the optimized communication and collaboration of multiple key players in the STEMI pathway, these time-critical, vulnerable patients can begin treatment promptly.
- Apple App Store
- Бесплатный
- Медицина
Рейтинг магазина
- -
MCSAID is an educational application dedicated to the topic of mechanical cardiocirculatory support for
patients with cardiogenic shock.
A basic section introduces the definitions and classifications of cardiogenic shock as well as some of the
common devices used for hemodynamic support in unstable patients.
There is an algorithm for helping understand the decision process depending on key clinical variables
such as cardiac output and PAPI. There are also several weaning and escalation algorithm.
A calculator section is available for some common hemodynamic variables used in MCS decision-making
and is available for quick-reference throughout the algorithm.
MCSAID is an educational application for medical professionals and is not intended for making medical diagnoses. Medical decisions must be made by licensed professionals with the entire context of a patient’s medical history. If you are seeking a medical diagnosis, contact your physician and if you are experiencing a medical emergency, call your local emergency medical services.
- Apple App Store
- Бесплатный
- Медицина
Рейтинг магазина
- -
STEMIcathAID vs. MCSAID ranking comparison
Compare STEMIcathAID ranking trend in the past 28 days vs. MCSAID
Rank
Нет данных
Рейтинг STEMIcathAID против MCSAID в сравнении по странам
Сравните динамику рейтинга STEMIcathAID за последние 28 дней с динамикой рейтинга MCSAID.
Нет данных для отображения
Сравните данные с любым сайтом, воспользовавшись бесплатной пробной версией
STEMIcathAID VS.
MCSAID
декабрь 11, 2024